[S-16] Symposium 16
Autoimmune epilepsy

[S-16-3] Clinical management for an acute phase of autoimmune epilepsy

^○Yuto Uchida^1,2, Daisuke Kato³, Kiyohito Terada⁴, Noriyuki Matsukawa¹ (1.Nagoya City University, Japan, 2.Toyokawa City Hospital, Japan, 3.Nagoya University, Japan, 4.Yokohama Minoru Epilepsy&Developmental Clinic, Japan)

The epilepsy syndrome of autoimmune etiology, namely, autoimmune epilepsy has attracted attention in recent years. Neural-specific autoantibodies such as anti-NMDA-R and LGI1 antibodies were found, which cause autoimmune epilepsy. Seronegative patients are also existed, and a diagnostic algorithm is required for the diagnosis. Immune therapy should be started in the acute phase as soon as possible in addition to antiepileptic therapy. Especially, new-onset refractory status epilepticus (NORSE) is one of the most challenging status in terms of treatment of acute phase. On the other hand, the presence of smoldering type should be noted with clinical variabilities of autoimmune epilepsy. In this session, pathophysiology, proposal for diagnostic algorithm, management of acute phase, and clinical variabilities of autoimmune epilepsies will be presented by experts in this field.

Apr 2009 - Mar 2010: Resident, Anjo Kosei Hospital
Apr 2010 - Mar 2011: Resident, Nagoya City University
Apr 2011 - Jun 2014: Senior Resident, Tosei General Hopital
Jul 2014 - Mar 2016: Neurologist, Toyokawa City Hospital
Apr 2016 - Today: Postdoctoral Researcher, Nagoya City University Graduate School of Medical Sciences; Neurologist, Toyokawa City Hospital